Holen Sie sich die Stockscreener-App
77.91
3.18%
-2.56
Schlusskurs vom Vortag:
$80.47
Offen:
$79.75
24-Stunden-Volumen:
429.62K
Relative Volume:
0.59
Marktkapitalisierung:
$6.08B
Einnahmen:
$754.05M
Nettoeinkommen (Verlust:
$73.06M
KGV:
85.87
EPS:
0.9073
Netto-Cashflow:
$164.23M
1W Leistung:
-0.22%
1M Leistung:
+2.53%
6M Leistung:
+64.82%
1J Leistung:
+119.40%
1-Tages-Spanne:
$77.90
$80.43
1-Wochen-Bereich:
$76.65
$81.41
52-Wochen-Spanne:
$35.12
$82.94
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
77.91 | 6.12B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-09-29 | Eingeleitet | TD Cowen | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
| 2020-06-29 | Bestätigt | BofA Securities | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-12-12 | Bestätigt | Wedbush | Outperform |
| 2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Kiniksa Director Barry D Quart Donates 2,600 Class A Shares to Donor Advised Fund - Kalkine Media
Kiniksa (NASDAQ: KNSA) director gifts 2,600 shares to donor fund - Stock Titan
Kiniksa (KNSA) Earnings Report: EPS Comes in Below Forecast in the Reported Period; Trading Move: Shares Move 2.88% Lower on the DayEarnings Revision Downgrade - vinanet.vn
Handelsbanken Fonder AB Makes New $1.34 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Compelling Affordable Growth Story - ChartMill
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 3. - GuruFocus
Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 - sharewise.com
Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N - TradingView
KNSA: ARCALYST drives record growth as pipeline advances and patient access, awareness, and satisfaction rise - TradingView
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Promising Outlook with 28% Potential Upside - DirectorsTalk Interviews
Kiniksa Pharmaceuticals (KNSA) Holds Near $76.53 as Bulls Eye $80.36 ResistanceBPI Bull Correction - vinanet.vn
Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (NASDAQ:KNSA) - TradingView
Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)? - simplywall.st
Kiniksa Pharmaceuticals International, plc $KNSA Stake Raised by The Manufacturers Life Insurance Company - MarketBeat
Kiniksa Pharmaceuticals to present at Canaccord Genuity Growth Conference on August 12, 2026 - Pluang
Kiniksa’s Aug. 12 fireside chat will stream live online - Stock Titan
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Kiniksa Pharmaceuticals International PLC (KNSA) Stock News Today - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Lazard Asset Management LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
31,391 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Bought by Financial Enhancement Group LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Janus Henderson Group PLC - MarketBeat
Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Strong Earnings Are Of Good Quality - 富途牛牛
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Unlocking A 33.5% Upside Potential - DirectorsTalk Interviews
Dimensional Fund Advisors LP Purchases 128,417 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook - The Globe and Mail
Kiniksa Pharmaceuticals International, plc (KNSA) director sells and gifts shares - Stock Titan
Kiniksa Pharmaceuticals (KNSA) Slides 5.2% to $74.14 as Key Support Level LoomsSmart Beta Flow - vinanet.vn
Kiniksa Pharmaceuticals (KNSA) Drops 3.39% as Stock Approaches Key Support LevelDiamond Pattern - vinanet.vn
KNSA Maintained by Canaccord Genuity -- Price Target Raised to $98 - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $107.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $98.00 - MarketBeat
Kiniksa Pharmaceuticals International, plc Stock 12‑Month Price Target Raised to $79.62, Implies 25% Upside - TradingView
Stronger Q2 Results And Higher 2026 Outlook Might Change The Case For Investing In Kiniksa (KNSA) - simplywall.st
KNSA Looks 59.8% Overvalued on GF Value™ After Q2 Earnings Surge - GuruFocus
KNSA Looks 58.0% Overvalued on GF Value™ as Shares Surge 22.7% - GuruFocus
KNSA Looks 59.0% Overvalued on GF Value™ as Shares Surge Amid Mi - GuruFocus
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $99 From $72, Maintains Outperform Rating - marketscreener.com
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week HighWhat's Next? - MarketBeat
KNSA: Record ARCALYST sales and strong pipeline progress drove raised 2026 guidance and cash growth - TradingView
Kiniksa Pharmaceuticals International, plc Provides Earnings Guidance for Year 2026 - marketscreener.com
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates - Yahoo Finance
KNSA: Q2 2026 delivered 55% YoY ARCALYST sales growth and raised 2026 revenue guidance to $980–$995M - TradingView
Is Kiniksa Pharmaceuticals (KNSA) Overvalued After Q2 Earnings B - GuruFocus
Kiniksa Pharmaceuticals International (KNSA) Reports Q2 2026 Numbers - AlphaStreet
Kiniksa Pharmaceuticals stock rises 2% on raised guidance, revenue beat By Investing.com - Investing.com Nigeria
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.28 - marketscreener.com
Rubric Capital Management LP Acquires 421,347 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.66%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):